Lytix Biopharma: NOK 61m Capital Injection - Redeye
Bildkälla: Stockfoto

Lytix Biopharma: NOK 61m Capital Injection - Redeye

Redeye is optimistic about the directed share issue announced last week and a potential subsequent offering. It significantly strengthens the balance sheet.

Redeye is optimistic about the directed share issue announced last week and a potential subsequent offering. It significantly strengthens the balance sheet.
Börsvärldens nyhetsbrev